 |
|
sapacitabine
An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the deoxycytosine analogue CNDAC (2'-Cyano-2'-deoxyarabinofuranosylcytosine), which is then phosphorylated into the active triphosphate form. As an analogue of deoxycytidine triphosphate, CNDAC triphosphate incorporates into DNA strands during replication, resulting in single-stranded DNA breaks during polymerization due to beta-elimination during the fidelity checkpoint process; cell cycle arrest in the G2 phase and apoptosis ensue. The unmetabolized prodrug may exhibit antineoplastic activity as well. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code names: | | CS-682
CYC682 | | | | Chemical structure name: | | N-[1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl]-2-oxo-1,2-dihydropyrimidin-4-yl}hexadecanamide | | |
|
|
